The varied protocols researchers use to create organoids result in very heterogeneous organoids, and so standardisation of tools and protocols, and automated production will be among the most important drivers of advancements in this field. The creation and use of standardised organoids will increase reproducibility of results, replicability, and provide the experimental control required for clinical translation.
This will in turn increase the ease of interdisciplinary collaboration, which could help solve lingering problems such as the difficulty of connecting different organoids to each other on a chip, or the development of realistic vascular networks rather than the microfluidic imitations currently used.
After these problems are solved, automation can scale up biomanufacturing: robotically produced organs can have nearly identical numbers and types of cells, for example. This could help with the development of bioreactors, which would be necessary for the fabrication of entire organs.